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itric Oxide Replacement Therapy*
ommaso Gori, MD, PHD,†
ohn D. Parker, MD, FACC‡
iena, Italy; and Toronto, Canada
rganic nitrates are among the oldest and most commonly
sed drugs for the treatment of cardiovascular disease. In the
hort term, nitrates have a rapid onset of action, lowering
lood pressure and cardiac filling pressures, and they are
sed to treat episodes of angina for short-term control of
lood pressure and in the treatment of pulmonary conges-
ion. Despite the wide clinical use of these drugs and a large
ody of research in this field, it is interesting to note that
60 years after Ascanio Sobrero first synthesized nitroglyc-
rin, we remain with three questions of fundamental im-
ortance: 1) How do nitrates work? 2) Why do nitrates stop
orking upon continuous administration? and 3) What are
he long-term effects of nitrate therapy on clinical outcome?
nterestingly, these questions appear to be closely interrelated.
See page 624
Ignarro et al. (1) apparently answered the first of these
uestions some 20 years ago when they hypothesized that
itric oxide (NO) release mediates the effects of nitrates.
ithin this conceptual construct, nitrates are believed to be
rodrugs that undergo denitrification within the vascular
all. The enzymatic pathway involved in this denitrification
rocess has remained uncertain, with a number of candidate
nzymes suggested, although recent evidence points to an
mportant role for mitochondrial aldehyde dehydrogenase
2). A differential capacity to biotransform nitrates to NO
xplains the selectivity for certain vascular beds and the
elatively low effect on resistance arteries (3). Because they
re considered to exert their vascular effect through the
elease of NO (or some NO adjunct), nitrates have been
onsidered to be the prototypical endothelium-independent
NO-dependent) vasodilators. Of note, recent experimental
vidence seems to challenge these earlier conclusions be-
ause: 1) 60% of the arterial vasodilatory effect of nitroglyc-
rin is, at least in vitro, mediated by opening of potassium
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ospitals, Toronto, Canada. Dr Gori is the recipient of a Rientro dei Cervelli grant,otalian Ministry of Research.hannels in endothelial cells (4); 2) recent observations
uggest that nitroglycerin might not act through NO release
5); and 3) sustained exposure to nitrates causes a marked
mpairment of endothelium-dependent vasodilatation, an
mportant parameter of vascular function with prognostic
mplications (6,7). This impairment in endothelium-
ependent vasomotor responses appears to be associated
ith an increased bioavailability of free radical species,
mong which superoxide anion and peroxynitrite are the
est characterized. These observations, taken together, sug-
est that nitrates have profound interactions with the
ndothelium, a finding that challenges the traditional con-
eptual framework.
An unbalanced redox equilibrium also has been advocated
o explain the pathophysiology of nitrate tolerance. The past
ecades of research into this area have documented that
olerance is a multifactorial phenomenon based on exhaus-
ion of cofactors, inactivation, and altered expression of
everal enzyme systems. Although the increased production
f reactive oxygen and/or nitrogen species appears to rep-
esent the common trigger for these abnormalities, the
henomenon of tolerance seems to result from abnormali-
ies developing at a number of levels, including reduced
itrate biotransformation, reduced NO signal transduction,
s well as counterregulatory responses (8,9).
The increasing awareness that nitrates cause abnormali-
ies in endothelial function and are associated with increased
ascular production of radical species has prompted specu-
ation concerning the effect of these agents on clinical
utcome during sustained therapy. Traditionally, it has been
uggested that NO has beneficial effects on vascular func-
ion, based on its antiproliferative, antioxidant, and anti-
therogenic capacities. As such, it has been suggested that
xogenous (nitrate-released) NO might have the same
roperties (10). Concurrently, evidence that sustained ni-
rate therapy is associated with an increase in the production
f proatherogenic oxygen free radicals (11) would suggest
hat the safety of long-term nitrate therapy requires system-
tic review. Importantly, these hypotheses have never been
ested in large-scale, long-term clinical trials.
In this issue of the Journal, Mu¨ller et al. (12) demonstrate
hat large doses of isosorbide mononitrate (ISMN), admin-
stered using an eccentric schedule, have antioxidant and
ndothelial protective effects in an animal model of hyper-
holesterolemia. Their data strongly support the hypothesis
hat ISMN-derived NO can substitute for the lack of
ndogenous NO production and can also actually protect
he endothelial NO production. Although this hypothesis is
nteresting, one limitation of this article is that all studies
ere conducted early (3 h) after the morning dose of ISMN,
fter a 17-h dose-free interval. As the authors discuss, if
easures of superoxide (and endothelium-dependent vaso-
otor responses to acetylcholine) had been made at later
ime points after dosing, different results might have been
bserved because this early testing period may have occurred
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pecies production.
Among the data presented in the paper (12), those
egarding the effect of ISMN on morphologic evidence of
therosclerosis are the most striking. Although a high-
holesterol diet caused a fourfold increase in intima-media
hickness, this effect was significantly attenuated (approxi-
ately threefold compared with normal chow) after eccen-
ric ISMN administration. Collectively, the data presented
upport the concept that ISMN, administered in very high
oses using an eccentric dosing schedule, has the potential
o have protective vascular effects in the setting of hyper-
holesterolemia.
Although such results are of potential clinical importance,
hese observations, made in a small animal model, will not
ecessarily translate into clinically beneficial effects in hu-
ans. Importantly, the therapeutic regimen used in the
resent article, although allowing a 17-h nitrate-free daily
nterval, caused evidence of “moderate” nitrate tolerance,
ikely due to the high dose of ISMN. This evidence might
imit the possibility of transferring the beneficial effects of
SMN to clinical practice because: 1) regimens resulting in
he development of tolerance would not be beneficial in the
elief of symptoms; and 2) human studies have demon-
trated potential complications during intermittent nitrate
egimens (13).
In summary, the data presented by Mu¨ller et al. (12) are
nteresting and reserve confirmation in humans. Until re-
ently, few studies addressed the effect of nitrate therapy on
linical outcome in patients with stable coronary artery
isease (CAD). Large-scale trials in the postinfarction
etting failed to demonstrate a significant effect of nitrates
n clinical outcome. Unfortunately, both of these studies
ad short-term follow-up periods and suffered from a high
ercentage of open-label therapy in the control group
14,15). The shortcomings of these previous trials empha-
ize the need for long-term outcome studies examining the
ffect of nitrate therapy in patients with stable CAD.
vidence of a beneficial effect from angiotensin-converting
nzyme inhibition (16) has been provided recently, and data
n the effect of long-acting nifedipine are soon to be
eported (17). Nicorandil also has been demonstrated to
educe mortality, but the relative importance of its NO
onor properties versus the direct effect on potassium
hannel currents remains to be clarified (18). The existence
f these large-scale studies examining clinical outcome in
atients with stable CAD confirms their feasibility. It also
mphasizes that the organic nitrates remain the only class of
nti-ischemic/antianginal agents that have never been tested
n long-term, large-scale clinical outcome studies. The time
as come for the planning and completion of appropriately
esigned clinical trials of this type. Interestingly, these
tudies will also have to investigate whether treatment
ffects may be variable depending on the specific nitrate
dministered (19). The need is clear; the challenge is to findhe funding and scientific leadership to conduct such stud-
es.
The data presented in this issue of the Journal are relevant
ecause they place new hope on the treatment of angina and
he prevention of atherosclerosis. However, two aspects of
itrate therapy have to be considered when interpreting
hese data: on one side, the antiatherosclerotic effects of NO
donors), and on the other, the observation that, after
ontinuous treatment, nitrates may actually cause endothe-
ial dysfunction and sympathetic activation (6,7,20), both
ith potential negative prognostic influence. Future re-
earch is needed to investigate the mechanisms underlying
his dichotomy. As well, the evidence of potential risks
ssociated with tolerance-inducing regimens emphasizes the
mportance of following published recommendations for
itrate use (21). Furthermore, because nitrates are among
he most commonly prescribed agents for patients with
table angina pectoris, a century after their introduction in
linical practice, it is definitely time for a large-scale,
andomized, prospective human trial investigating their
ong-term effects, as advocated by the authors. However,
urning their question around, the first reassurance that has
o come from this trial, before investigating whether long-
erm therapy with organic nitrates has antiatherogenic
ffects, is whether or not it is actually safe in patients with
hronic CAD.
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